Simcere Sells 99.9% Stake In Jilin Bodapharmaceutical To Investment Firm
This article was originally published in PharmAsia News
Executive Summary
Simcere Pharmaceutical Group said it has sold its 99.9% stake in Jilin Bodapharmaceutical to an investment firm, Zhuhai Rongding Equity Investment Partnership for $65 million.